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Abstract: Vasomotor symptoms (VMS) are among the most bothersome complaints of
postmenopausal women. To date, the most widely studied and effective treatment for VMS is
hormone replacement therapy, consisting of estrogen (in women without a uterus) or estrogen
plus progestin (in women with a uterus). Traditionally, oral estrogens have been used for
treatment. However, over the years, additional estrogen formulations have been developed
including transdermal patches; vaginal rings, creams, and tablets; and injectable preparations.
Two newer formulations are transdermal estrogen spray and estradiol topical emulsion. This
review evaluates the current literature assessing the use of these two newer formulations for
the treatment of VMS associated with menopause.
Keywords: menopause, vasomotor symptoms, transdermal estrogen spray, estradiol topical
emulsion

Introduction
Although all women will be subject to menopause and the cessation of menses, not
all women will experience its associated symptoms. Of the associated symptoms,
vasomotor symptoms (VMS) are the most bothersome. They may include hot flashes
(rapid onset of intense heat sensation, sweating, and flushing lasting approximately 5 to
10 minutes) and/or night sweats.1–3 They are the leading reason menopausal women
seek medical care as can be illustrated by a 2002 Gallup poll of menopausal women
showing that hot flashes, night sweats, mood disturbances, and sleep disturbances were
the top four reasons for which medical attention was sought at this time in their lives.4
Overall, VMS are estimated to affect 14% to 51% of premenopausal women, 35% to
50% of perimenopausal women, and 30% to 80% of postmenopausal women.3
On average, most women experience VMS for 6 months to 2 years; however,
approximately 10% of women report experiencing VMS for 10 or more years.4,5
In total, it is estimated that 60% of peri- and postmenopausal women seek care for
their menopausal symptoms.6
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There is currently no consensus on the pathophysiology of menopause-associated VMS;
however several mechanisms have been proposed. One is a narrowing of the thermoregulatory threshold between sweating and shivering in the hypothalamus.7 This narrowing
is thought to be caused by decreased levels of circulating serotonin, increased levels
of norepinephrine, and/or decreased estrogen concentrations.1,5 The perimenopausal
decline in ovarian estradiol production results in diminished negative-feedback effects
International Journal of General Medicine 2010:3 147–151
147
© 2010 Egras and Umland, publisher and licensee Dove Medical Press Ltd. This is an Open Access article
which permits unrestricted noncommercial use, provided the original work is properly cited.

Dovepress

Egras and Umland

on the anterior pituitary, leading to a compensatory increase
in the secretion of leuteinizing hormone from the pituitary,
a process regulated by gonadotropin-releasing hormone in the
hypothalamus.8 Pulsatile surges of gonadotropin-releasing
hormone due to estrogen deficiency affect the hypothalamic
neurons that control central thermoregulation centers.9
It has also been hypothesized that the ratios of the specific
types of estrogen (ie, estradiol or estrone) may be better
correlated with the occurrence of VMS than the overall
circulating level of estrogen.10 Compared to premenopausal
women in whom the most abundant circulating estrogen
is estradiol, the more potent form of estrogen, throughout
the peri- and postmenopausal years, the most abundant
circulating estrogen shifts to estrone, a much less potent form
of estrogen.8 Further, the occurrence of VMS has been found
to correlate better with an acute decline in estrogen levels
than with the actual measured levels of estrogen.5

Estrogen therapy (ET)
Given the above proposed mechanisms for VMS, it is no
surprise that hormone replacement therapy (HT), consisting of
estrogen (in women without a uterus) or estrogen plus progestin
(in women with a uterus [to protect against endometrial
hyperplasia or cancer]), is the most widely studied and most
effective treatment option for relieving VMS and is considered
the standard of care for women with moderate-to-severe
VMS.1,2 The AACE and ACOG recommend the use of HT at
the lowest effective dose and for the shortest duration possible
(preferably #5 years) in women for whom the potential benefits outweigh the potential risks.1,11 The 5-year cut-off for
HT is suggested because most women will experience spontaneous cessation of menopausal symptoms within 5 years of
onset.1 Use of HT for longer durations may be appropriate in
some women, such as those who judge the benefits of VMS

relief to outweigh the potential risks after failing an attempt
to discontinue HT, those with continued VMS who are also
at high risk for osteoporotic fractures, and those requiring
osteoporosis prevention who cannot take alternative therapies.2
Several weeks may be required to determine the efficacy of HT
in treating VMS.5 Contraindications to the use of HT include
breast or estrogen-sensitive cancers, undiagnosed vaginal
bleeding, endometrial hyperplasia, blood clotting disorder,
hypertension, liver disease, hypersensitivity to the active or
excipient compounds in HT.1
The recommendation that HT is the standard of care
for treating moderate-to-severe VMS is based on the
large body of evidence demonstrating the effectiveness
of estrogen or estrogen plus progestin in the reduction of
VMS frequency and severity. In fact, a meta-analysis of
24 double-blind, randomized, placebo-controlled trials
including a total of 3,329 subjects and ranging in duration
from 3 months to 3 years demonstrated a significant 75.3%
reduction in the frequency of hot flashes experienced per
week (weighted mean difference, −17.92, 95% confidence
interval [CI], −22.86 to −12.99) and a significant 87% reduction in the severity of symptoms (odds ratio [OR], 0.13; 95%
CI, 0.07 to 0.23) relative to placebo. The most frequently
used HT regimens noted in the meta-analysis included
oral estradiol, conjugated equine estrogens, and ethinyl
estradiol, with or without a 19-nor testosterone derivative.12
These relative reductions are significant considering that
the placebo response rate in this meta-analysis was 57.7%.
There are currently no data available to suggest that any
one formulation of estrogen or estrogen plus progestin is
clinically superior to another.5,11,13 Estrogen and progestin are
available in various oral, transdermal (patch, spray, and emulsion), vaginal, and injectable preparations. Table 1 illustrates
the recommended doses for these various products.

Table 1 Recommended dosing ranges for commonly used hormonal therapies used to treat vasomotor symptoms1,2,5,14
Drug

Daily dose

Estrogens
Conjugated equine estrogens
Micronized 17β-estradiol
Transdermal estradiol (patch)
Transdermal estradiol (spray)
Transdermal estradiol (emulsion)
Ethinyl estradiol
Vaginal estradiol ring
Progestins
Medroxyprogesterone acetate
Micronized progesterone
Norethindrone
Levonorgestrel
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0.3–0.625 mg
0.25–1 mg
14–100 μg
1.53–4.59 mg
3.84 g
0.01–0.02 mg
0.05–0.1 mg
2.5 mg (or 5 mg for 10–14 days/month)
100 mg (or 200 mg for 10–14 days/month)
0.14–0.25 mg (transdermal patch); 0.2–1 mg (orally)
0.075 mg
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ET dosage formulations
Traditionally, ET has been administered orally. However,
other routes of ET administration have been developed.
Transdermal formulations, such as the patch, spray and
topical emulsion, offer some advantages over oral estradiol
administration. These formulations avoid hepatic first pass
metabolism that is observed with the oral formulations and
that can result in the variable bioavailability of estrogen
and potentially the need for higher doses. In addition, these
dosage formulations have little or no risk for the development
of conditions such as hypertriglyceridemia, gallbladder
disease, and thromboembolism.15,16
However, while the transdermal administration bypasses
first pass metabolism and results in effective therapy at lower
estrogen doses, some concerns with this delivery system
do exist. These include variable systemic absorption, skin
irritation, and poor adhesion of the patches.17–19 Two newer
formulations, transdermal spray and topical emulsion, may
offer some advantages over both the orally administered and
transdermal patch estrogen. This review examines the clinical
data related to the use of the transdermal spray and topical
emulsion ET to treat VMS associated with menopause.

ET – transdermal spray
and topical emulsion
Presented here are summaries of the clinical trials evaluating
the effects of transdermal estrogen spray and estradiol topical
emulsion on VMS associated with menopause.

ET – transdermal spray
The transdermal estrogen spray is a clear spray that dries in
60 seconds and results in little to no skin irritation.20 It has been
shown that significant transfer of estradiol via skin-to-skin
contact does not occur; washing the application site 1 hour after
application does not affect absorption; and applying sunscreen
1 hour prior to application also does not affect absorption.21
In a phase III, randomized, double-blind, placebo-controlled,
parallel-group trial, Buster et al investigated the safety and efficacy of a transdermal estradiol spray.20 Postmenopausal women
(n = 454) with at least 8 moderate-to-severe hot flashes per day
(recorded in a daily diary) were randomly assigned to receive
1, 2, or 3 sprays of estradiol; or 1, 2, or 3 sprays of placebo to
the inner forearm. One spray of estradiol delivered 1.52 mg of
estradiol. The primary efficacy endpoint was the change in frequency and severity (0, none; 1, mild; 2, moderate; or 3, severe)
of moderate-to-severe hot flashes from baseline to weeks 4 and
12. For the 3 spray group, there was a reduction in the frequency
of hot flashes per day of −6.64 ± 4.23 at week 4 and a reduction
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of −8.44 ± 4.50 at week 12. This was statistically significant
when compared to placebo (P , 0.001). Similar results were
observed in the 2 spray group, with a frequency reduction of
−7.30 ± 6.93 at week 4 (P = 0.003) and −8.66 ± 6.65 at week 12
(P = 0.010). There was also a statistically significant reduction of
hot flashes from baseline in the 1 spray group with a frequency
reduction of −6.26 ± 4.01 (P = 0.001) at week 4 and −8.10 ± 4.02
(P , 0.001) at week 12 compared to placebo.
For the 3 spray group, changes in the severity score of the
moderate-to-severe hot flashes decreased from 2.58 ± 0.25
at baseline to 2.15 ± 0.73 and 1.50 ± 1.06 at weeks 4 and
12, respectively. These findings were statistically significant
(week 4, P = 0.003; week 12, P , 0.001) when compared to
placebo (baseline, 2.54 ± 0.24; week 4, 2.41 ± 0.58; week 12,
2.23 ± 0.79). Similar results were observed in the 2-spray
group with the severity score being 1.97 ± 0.87 at week 4
and 1.63 ± 1.07 at week 12 compared to a baseline score
of 2.54 ± 0.21. These results were statistically significant
(week 4, P = 0.016; week 12, P = 0.041) when compared to
placebo (baseline, 2.54 ± 0.21; week 4, 2.29 ± 0.71; week 12,
2.00 ± 0.96). For the 1-spray group, at week 12, the severity
decreased by −1.04 compared to −0.26 ± 0.60 in the placebo
group (P , 0.001) and there was a trend towards significance
at week 4 (P = 0.057). It was also shown that 74.3% to 85.5%
of women treated with transdermal estradiol spray had a $50%
reduction in hot flash frequency when compared to baseline.
The Greene Climacteric Scale scores, focusing on the vasomotor domains of hot flashes and night sweats, also showed a
significant improvement in VMS for those women treated with
the transdermal estradiol spray. While the baseline and week 12
scores were not reported, it was noted that in the 3 spray group,
there was a reduction of 1.7 in the hot flush score compared
to 0.9 in the placebo group (P , 0.001); in the 2-spray group,
there was a reduction of 1.3 compared to 0.9 with placebo
(P = 0.018); and in the in the 1-spray group, there was a reduction of 1.3 compared to 0.8 with placebo (P = 0.003). All of
these results were statistically significant.
The most common adverse events reported were headache and breast tenderness. There were no reports of death,
pulmonary emboli, venous thromboemboli, myocardial
infarction, or stroke. The spray was associated with little to
no erythema. Overall, the transdermal estradiol spray was
found to be safe and effective in the treatment of VMS.20

ET – topical emulsion
Another alternative to current ET formulations is the micellar nanoparticle estradiol emulsion that is applied as a
topical lotion. The emulsion has moisturizing qualities and
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when applied to the skin, forms a drug depot. The estradiol
gradually diffuses through the skin and into the blood stream.
The pharmacokinetic profile has shown minimal fluctuations
in estradiol serum levels.22
In a phase III, multicenter, randomized, double-blind,
placebo-controlled trial, Simon and the Estrasorb Study group
investigated the safety and efficacy of a topical estradiol
emulsion.22 Postmenopausal women (n = 200) with 120 or
more moderate-to-severe hot flashes over a 2-week period
were randomly assigned to receive placebo emulsion or
estradiol topical emulsion (8.6 mg of 17β-estradiol in 3.45 g
of emulsion) to be applied daily to the thigh and calf of both
legs until fully absorbed for 12 weeks. The primary efficacy
endpoint was the change in frequency of moderate-to-severe
hot flashes from baseline to weeks 4 and 12. There was a
significant decrease in the frequency of hot flashes per day at
week 4 (P , 0.05) which continued throughout the treatment
period with the peak reduction seen at week 12 (−11.1 ± 6.8
hot flashes/day for estradiol treatment arm versus −7.2 ± 5.4
for placebo, P , 0.001).
The secondary efficacy endpoint was the change in the
severity of hot flashes using a severity score index. Hot
flashes were rated as: grade 1 mild, grade 2 moderate, or grade
3 severe. Statistically significant decreases in the daily severity score index was observed at weeks 4, 8 and 12 (P , 0.001)
for the estradiol treatment arm versus placebo.
The most common adverse events reported in the
treatment arm were endometrial/uterine wall thickening,
infection, breast pain, application-site reaction, pruritis,
vaginal bleeding and vaginal moniliasis. Overall, the estradiol
topical emulsion was found to be safe and effective in the
treatment of VMS.22
While the estradiol emulsion was found to be safe
and effective in the treatment of VMS, in order to have
this effect, large doses of the estrogen hormone must be
applied topically. This raises concerns as to whether or not
the hormone may be transferred to others via skin-to-skin
contact. An open-labeled, nonrandomized clinical study
p erformed by Taylor et al investigated the systemic
a bsorption of estradiol in partners of postmenopausal
women. Fourteen postmenopausal women and their partners
were enrolled in the study. The women applied 1.74 g of
estradiol topical emulsion (containing 2.5 mg of estradiol
per gram) to the thigh and calf of both legs for 2 consecutive days. Two hours after application, the male partner
rubbed his left forearm vigorously back and forth across
the application site for 2 minutes. This was repeated on the
male’s right forearm 8 hours after application. Serum con-
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centrations of estradiol, estrone, and estrone sulfate were
measured prior to estradiol application and at 1, 2 and 8
hours after application for the females, and at 1, 2, 4, 8, 12,
18 and 24 hours after their partners had attempted transfer
of the estradiol topical emulsion. Geometric means analysis
showed that the area under the serum concentration-time
curve from 1 to 8 hours (AUC1–8) and the maximum concentration (Cmax) for estradiol, estrone, and estrone sulfate
increased 2- to 3-fold after the second application. These
results were statistically significant. Geometric means
analysis also showed a significant increase in the area
under the serum concentration-time curve from 0–24 hours
(AUC0–24) and Cmax for estradiol, estrone, and estrone sulfate
in the male partners on day 2 when compared to baseline.
In particular, the concentration of estradiol increased 25%
from 17.0 ± 4.3 to 21.0 ± 4.4 pg/mL. However, these levels
still remained below the upper limit of the normal range for
men (45 pg/mL).23

Summary
A variety of estrogen formulations exist for the treatment of
menopause-related VMS. Clinical trials have demonstrated
that transdermal spray delivery and topical emulsion are
both effective methods for this indication and appear to be
safe for use in postmenopausal women. In addition, both
of these formulations avoid first pass metabolism that may
likely result in more consistent absorption, more predictable
estrogen concentrations, and easier dosage adjustments when
needed. The transdermal estradiol spray was well tolerated
by women with headache and breast tenderness being the
most commonly reported adverse events.20 While the topical
estradiol emulsion is effective at decreasing VMS, more
studies need to be done to assess skin-to-skin transfer in more
detail. The current data is very limited and only observed
transfer after two applications. It is unknown what effects
the consistent use over time may have on transfer to one’s
partner. Overall, the transdermal estrogen sprays and topical
estradiol emulsion are effective and acceptable alternatives
to traditional oral and transdermal patch estrogen used in the
treatment of VMS in postmenopausal women.
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